|
全民健康保險藥品給付規定 |
|
See related Menopur powd for inj[美諾孕 乾粉注射劑] information |
|
|
|
製造商 |
Ferring |
|
代理/經銷商 |
Ferring |
|
成份 |
Menotrophin (human menopausal gonadotrophin) equiv to FSH 75 iu & LH 75 iu |
|
適應症 |
Infertility in male & female. |
|
用量 |
By IM or SC inj. Female Initially 75-150 iu of FSH (1-2 vials Menopur) daily & gradually adjusted if necessary until an adequate response is achieved. To induce ovulation, 5000-10,000 iu HCG should be administered by IM inj after the last dose of HMG. A 2nd HCG administration of 5000 iu may be given 7 days afterwards to improve luteal function. Male 1-2 vials of Menopur administered 3 times/week, along with 3000 iu of HCG/week. This dosage should be maintained for 10-12 wks, or until there is evidence of improvement in spermatogenesis. |
|
美國食品藥物管理局之懷孕等級 |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
禁忌 |
Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus, ovaries & breasts. |
|
注意事項 |
Ovarian activity should be checked prior to administration. Treatment should be immediately discontinued if unintentional hyperstimulation occurs. Pregnancies that occur after fertility treatment w/ gonadotrophins are more likely to be terminated in spontaneous abortions than normal pregnancies. |
|
不良反應 |
Ovarian hyperstimulation, ascites, hydrothorax, oliguria, hypotension, thromboembolism, hypersensitivity reactions, fever, nausea & vomiting, inj site reactions, unintentional multiple pregnancies.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
Ferring |
|
Distributor: |
Ferring
|
|
|
|
